What Is Metastatic Castrate Resistant Prostate Cancer (mCRPC)?

Castrate Resistant Prostate Cancer is a type of advanced prostate cancer. In cases of Castrate Resistant Prostate Cancer, the cancer is no longer responding to treatment that lower testosterone levels. Additionally, there are signs of growth, including a rising prostate-specific antigen, even with the lowered levels of testosterone.

Lutetium-177 Prostate-Specific Membrane Antigen (PSMA) Therapy

Lutetium-177 Prostate-Specific Membrane Antigen Therapy (“Lu177 PSMA Therapy”) is a Nuclear Medicine radionuclide treatment that allows for highly specific and targeted radiation therapy used in the treatment of prostate cancer.

Lu177 PSMA Therapy is often used for metastatic Castrate Resistant Prostate Cancer (mCRPC).

How Does Lutetium-177 PSMA Therapy Work?

Prostate-Specific Membrane Antigen (PSMA) is a type II transmembrane glycoprotein that is found in concentrations 100-1000 times higher in prostate cancers as compared with normal tissue.

PSMA is an excellent target for radionuclide imaging and therapy as it is highly expressed in prostate cancers. Small molecule PSMA ligands allow for rapid targeting of the prostate cancer cells.

When these PSMA ligands are bound with Lu177 radionuclides, they act as a “magic bullet” delivery system allowing for targeted radiotherapy of prostate cancer cells.

What Are the Expected Outcomes of Lu177 PSMA Therapy?

Lu177 PSMA Therapy aims to reduce tumour volume and stop the growth of cancer.

Lu177 PSMA therapy has proven anti-tumour activity and safety in treating patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) and is an ideal therapeutic option for patients who do not tolerate chemotherapy well or have extensive bone marrow involvement.

Lu177 PSMA therapies have shown trends towards Prostate-Specific Antigen (PSA) reductions, lengthening overall survival and progression-free survival, with generally mild and transient toxicities.

What Are the Potential Side Effects of Lu177 PSMA Therapy?

Aside from Prostate cancers, there are other organs and normal tissue that express PSMA antigens.

These include the salivary glands, bone marrow, kidneys, and small intestines. As such, these organs will be exposed to a small amount of radiation during therapy.

Approximately 10-20% of patients will experience a drop in blood cells (e.g. red blood cells, white blood cells, platelets), which is typically transient in nature (approximately 6 weeks), with the recovery of blood levels expected.

Approximately 10-20% of patients will experience a decrease in salivary production (Xerostomia). Additionally, some patients may experience side effects of nausea and fatigue, which is usually transient.

Who Will Benefit From Lu177 PSMA Therapy?

Patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) are the ideal candidates for Lu177 PSMA Therapy.

Most patients who undergo Lu177 PSMA therapy are heavily pre-treated, typically with multiple chemotherapy and androgen deprivation therapy courses.

However, increasing data shows that patients who undergo Lu177 PSMA treatments earlier have better outcomes than heavily pre-treated populations.

What Are the Contraindications to Lutetium-177 PSMA Therapy?

Relative contraindications

  • Impaired renal function (GFR < 40 mL/min)
  • Impaired marrow function (platelet < 75 x 109/L, Hb < 90 g/L)
  • Recent radiotherapy (6 weeks)
  • Concomitant nephrotoxic drugs
  • Uncontrolled intercurrent illness or poor ECOG status
  • PSMA PET imaging showing poor tracer avidity
  • FDG PET imaging showing high FDG avidity without correlative PSMA expression

Discussion with your physician regarding the potential risks and benefits of therapy will be needed before commencing treatment.

What Are the Initial Investigations Needed for Lutetium-177 PSMA Therapy?

Imaging Studies

  • PSMA Positron Emission Tomography / Computed Tomography (PET/CT) scan within six months
  • Fluorodeoxyglucose (FDG) PET/CT scan is optional

Blood Investigations

  • Full Blood Count (FBC)
  • Renal Function Test
  • Prostate-Specific Antigen (PSA)
  • Alkaline Phosphatase (ALP)
  • Lactate Dehydrogenase (LDH)

Functional Status

  • ECOG Status Score

What to Expect During Treatment With Lutetium-177 PSMA Therapy?

Lu177 PSMA therapy can be done on an outpatient basis. It is expected to take approximately 4-6 hours in total, and you will be in the Nuclear Medicine department for the duration of the therapy.

Intravenous lines will be required for the therapy, and you will be asked to consume fluids to maintain good hydration (approximate 1.0 – 1.5L fluid throughout the day).

The Lu177 PSMA therapy will be given as a slow infusion over 10 minutes and will be followed by a standard saline infusion. You will be given anti-vomiting medications (e.g. Ondansetron) prior to the Lu177 PSMA infusion.

After the infusion is complete, you are free to walk around the Nuclear Medicine department, but you will be advised to avoid prolonged close contact with other patients. Additionally, small meals can be provided after the procedure.

Once radiation levels are within acceptable limits, you will be free to leave the Nuclear Medicine department. If you require admission for observation, we will make the necessary arrangements.

An appointment for the follow-up will be confirmed or arranged for you before discharge.

Useful Links

What is Theranostics, Cancer Cells, Theranostics Singapore, Dr Andrew Tan
, ,

What Is Theranostics?

What Is Theranostics? Theranostics is a viable method of treating cancer, especially when the cancer cells have spread or are at a more advanced stage and are unable to respond to other treatments. While there is still a lot of potential…
Coping With Prostate Cancer, Prostate Cancer Treatment, Theranostics for Prostate Cancer, Coping With Prostate Cancer

Coping With Prostate Cancer: Your Symptoms, Well-Being, and Finding Support

What Is Prostate Cancer? The prostate is a small gland located below the urinary bladder and surrounding the urethra (pelvic cavity). This gland is regulated by the testosterone hormone and produces seminal fluid or semen. Cancer occurs…
Lutetium-177, Prostate Specific Membrane Antigen, PSMA, Cancer Treatment, What to Expect, Theranostics, Theranostics Singapore, Dr Andrew Tan

What to Expect: Lutetium-177 Prostate-Specific Membrane Antigen (PSMA) Therapy

What Is Lutetium-177 Prostate-Specific Membrane Antigen (PSMA) Therapy?  Prostate-Specific Membrane Antigen (PSMA) is a type of receptor found on cell membranes throughout the body and is particularly increased on the cell surfaces of prostate…
Radium-223 Therapy, Xofigo, What to Expect, Theranostics, Theranostics Singapore, Cancer Treatment, Patient Information, Dr Andrew Tan

What to Expect: Radium-223 Therapy (Xofigo) 

What Is Radium-223 Therapy (Xofigo)?  Radium-223 Therapy (Xofigo) is a form of targeted radioactive therapy. It is a type of radioactive treatment that targets sclerotic bony metastases. What Is Prostate Cancer? Prostate cancer is one of…
Prostate Cancer, Cancer, Theranostics, Prostate Cancer Treatment, Nuclear Medicine

Prostate Cancer: Causes, Symptoms, Diagnosis, Treatment

What Is Prostate Cancer? Prostate cancer is one of the most common cancers in men. Statistically, it is known that 1 out of every ten men will be diagnosed with this disease. In the United States, the diagnosis is usually in the initial…

What are the expected outcomes of Lu177 PSMA Therapy?

The aim of the therapy is to reduce tumour volume and stop the growth of cancer.

Lu177 PSMA therapy has proven anti-tumour activity and safety in the treatment of patients with metastatic Castrate Resistant Prostate Cancer, and is an ideal therapeutic option for patients who do not tolerate chemotherapy well or have extensive bone marrow involvement. 

Lu177 PSMA therapies have shown trends towards Prostate Specific Antigen (PSA) reductions, lengthens overall survival and progression free survival, with generally mild and transient toxicities.

Aside from Prostate cancers, there are other organs and normal tissue that express PSMA antigens. These include the salivary glands, bone marrow, kidneys and small intestines. As such, these organs will be exposed to a small amount of radiation during therapy. 

Approximately 10-20% of patients will experience drop in blood cells (e.g. red blood cells, white blood cells, platelets), which is typically transient in nature (approximate 6 weeks), with recovery of blood levels expected. 

Approximately 10-20% of patients will experience a decrease in salivary production (Xerostomia). 

Some patients may experience side effects of nausea and fatigue, which is usually transient.

Patients with metastatic Castrate Resistant Prostate Cancer are the ideal candidates for therapy. 

Currently, most of patients who undergo Lu177 PSMA therapy are heavily pretreated, typically with multiple courses of chemotherapy and androgen deprivation therapy. 

However, there is increasing data that show patients who undergo Lu177 PSMA treatments earlier have better outcomes as compared to heavily pre-treated populations.

Relative contraindications

  • Impaired renal function (GFR < 40 mL/min)
  • Impaired marrow function (platelet < 75 x 109/L, Hb < 90 g/L)
  • Recent radiotherapy (6 weeks)
  • Concomitant nephrotoxic drugs
  • Uncontrolled intercurrent illness or poor ECOG status
  • PSMA PET imaging showing poor tracer avidity 
  • FDG PET imaging showing high FDG avidity without correlative PSMA expression

Discussion with the physician in regards to the potential risks and benefits of therapy will be needed prior to commencing therapy.

Imaging Studies

  • PSMA Positron Emission Tomography / Computed Tomography (PET/CT) scan within 6 months
  • Fluorodeoxyglucose (FDG) PET/CT scan is optional

Blood Investigations

  • Full Blood Count (FBC)
  • Renal Function Test
  • Prostate Specific Antigen (PSA)
  • Alkaline Phosphatase (ALP)
  • Lactate Dehydrogenase (LDH)

Functional Status

  • ECOG Status Score

Lu177 PSMA therapy can be done on an outpatient basis. It is expected to take approximately 4-6 hours in total, and you will be in the Nuclear Medicine department for the duration of the therapy. 

Intravenous lines will be required for the therapy, and you will be asked to consume fluids to maintain good hydration (approximate 1.0 – 1.5L fluid throughout the day). 

The Lu177 PSMA therapy will be given as a slow infusion over 10 minutes, and will be followed by a normal saline infusion. You will be given anti-vomiting medications (e.g. Ondensetron) prior to the Lu177 PSMA infusion. 

After the infusion is done, you are free to walk around the Nuclear Medicine department, but you will be advised to avoid prolonged close contact with other patients. Small meals can be provided after the procedure. 

Once radiation levels are within acceptable limits, you will be free to leave the Nuclear Medicine department. If you require admission for observation, we will make the necessary arrangements. 

An appointment for the follow-up will be confirmed or arranged for you prior to discharge. 

Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.
Therapies We Offer
Liver Cancer Therapy

Prostate Cancer Therapy

Neuroendocrine Cancer Therapy